



ISPOR Barcelona

Richard Macaulay PhD, Senior Director, Pricing & Market Access PAREXEL Intl London Llk

Andrew Walker PhD, former Scottish Medicines Consortium, NHS Greater Glasgow and Clyde; Now: Director, Salus Alba

Detlev Parow MD, Head of Health Care Management, DAK Gesundheit,

Bettina Ryll MD PhD, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University, Sweden

YOUR JOURNEY. OUR MISSION.®

© 2018 PAREXEL INTERNATIONAL CORP.

### SPEAKERS AND AGENDA



**Richard Macaulay** 

Senior Director, Pricing & Market Access PAREXEL Intl



**Andrew Walker** 

Ex-Scottish Medicines Consortium; Current: Director, Salus Alba



#### **Detley Parow**

Head of Pharmaceutical Department, DAK Gesundheit



### **Bettina Ryll**

Founder Melanoma Patient Network Europe

### Introduction to drug disinvestment

### **UK** national HTA perspective

DE regional payer perspective

Physician & patient perspective

### On the need, their experiences, & potential mechanisms for drug disinvestment

Each panelist will speak for 10 minutes and this will be followed by a 20minute panel discussion, and 10 minutes of Q&A from the audience

© 2018 PAREXEL INTERNATIONAL CORP. / 2

PAREXEL.



© 2018 PAREXEL INTERNATIONAL CORP. / 3

PAREXEL.

### HEALTHCARE COSTS ARE INCREASING WHILST BUDGETS ARE BEING CONSTRAINED NECESSITATING TRADE-OFFS



**Escalating costs** 





**Budgetary pressures** 

How can high-cost new therapies be reimbursed whilst managing the cost of care?

PAREXEL.

© 2018 PAREXEL INTERNATIONAL CORP. / 4

### ...AND NEW HIGH-COST THERAPY CLASSES WITH TRANSFORMATIONAL PATIENT BENEFITS ARE EMERGING

## Transformative therapy classes

### Gene therapies

## CAR ther

CAR-T cell therapies

### **Key features**

Transformational patient benefits

For diseases with severe unmet needs

Often in rare patient populations

### Consequences

Candidates for expedited regulatory approval

Approved on earlier clinical data packages

These therapies are often **very high-cost**, reflective of their patient benefits, manufacturing costs, and small patient populations

© 2018 PAREXEL INTERNATIONAL CORP. / 5

PAREXEL.

## DRUG DISINVESTMENT UNDERLIES TWO POTENTIAL KEY APPROACHES TO ADDRESSING THIS...



Re-allocating funding from already reimbursed treatments deemed to be of low value

2

Temporary reimbursement (at a discount) of new treatments until more robust evidence available

PAREXEL.

© 2018 PAREXEL INTERNATIONAL CORP. / 6

## ...HOWEVER, DESPITE BEING CONCEPTUALLY APPEALING, IN PRACTICE THEY CAN BE CHALLENGING...



Removing clinically effective options for **economic reasons** 

**Linkage** between savings and reimbursing new options is not often clear

Local-level implementation & incumbent financial structures can form barriers

Lack of patient equity – introducing a **time lottery** 

Is it even **needed? Physician** judgement on 'low value' options

PAREXEL.

© 2018 PAREXEL INTERNATIONAL CORP. / 7

...AND DISINVESTMENT ATTEMPTS TO DATE HAVE FACED SIGNIFICANT IMPLEMENTATION DIFFICULTIES...

Conditional financing (Netherlands)

Warfarin & NOACs

Erlotinib in EGFR M-/?
NSCLC (NICE)

Cancer Drugs Fund (UK) reforms?

PAREXEL.

© 2018 PAREXEL INTERNATIONAL CORP. / 8

### ...WE WILL ATTEMPT TO ADDRESS THE ISSUE OF DRUG DISINVESTMENT – BOTH ITS NEED & IMPLEMENTATION

# **DRUG DISINVESTMENT**IS IT NEEDED AND HOW COULD IT WORK?

We will hear perspectives from

**UK national HTA** 



Physician & patient



**Andrew Walker** 



**Detley Parow** 



**Bettina Ryll** 

© 2018 PAREXEL INTERNATIONAL CORP. / 9

PAREXEL.